Author:
Creutzig U,Körholz D,Niemeyer CM,Kabisch K,Graf N,Reiter A,Scheel-Walter H,Bender-Götze Ch,Behnisch W,Hermann J,Mann G,Ritter J,Zimmermann M
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference5 articles.
1. Berman E . A review of idarubicin in acute leukemia Oncology Huntingt 1993 7: 91–98
2. Creutzig U, Zimmermann M, Ritter J, Henze G, Graf N, Löffler H, Schellong G . Definition of a standard-risk group in children with AML Br J Haematol 1999 104: 630–639
3. Creutzig U, Ritter J, Zimmermann M, for the AML-BFM Study Group . AML-BFM 93: risk-adapted therapy and randomization in children with AML: preliminary results Acute Leukemias VII 1999 (in press)
4. Daghestani AN, Arlin Z, Leyland-Jones B, Gee TS, Empin S, Mertelsmann R, Budmann D, Schulman P, Baratz R, Williams L, Clarkson BDYCW . Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia Cancer Res 1985 45: 1408–1412
5. Wiernik PH, Banks PLC, Case DC Jr, Arlin ZA, Perlman PO, Todd MB, Ritch PS, Enck RE, Weitberg AB . Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood 1992 79: 313–319
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献